ArticleEye (London, England)2022
Intravitreal injections: past trends and future projections within a UK tertiary hospital.
Article in Eye (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06817915 (LMU Project on the Impact of Reviewing AI Annotated SD-OCT Therapy Assistance Reports on Ophthalmologists' Treatment Decision-making for Anti-VEGF Therapy in NAMD Patients), which is not on this map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
LMU Project on the Impact of Reviewing AI Annotated SD-OCT Therapy Assistance Reports on Ophthalmologists' Treatment Decision-making for Anti-VEGF Therapy in NAMD Patients
Who cites it
48 citing papers in PubMed.
- Efficacy and safety of prophylactic simultaneous intravitreal moxifloxacin injection with standard intravitreal anti-VEGF injection procedure in cases of cystoid macular edema and macular neovascularization.BMC ophthalmology · 2025Trial
- Cost consequences of task-shifting intravitreal injections from physicians to nurses in a tertiary hospital in Norway.BMC health services research · 2023Trial
- Trial
- Modified Delphi expert consensus on the optimal intravitreal treatment pathway for centre involving diabetic macular oedema patients within the National Health Service.BMJ open ophthalmology · 2026Article
- Evaluating the effectiveness of different topical anesthetic methods in reducing pain during intravitreal injections: a systematic review and meta-analysis.International journal of retina and vitreous · 2026Review
- Aflibercept 8 mg treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: guidance from a UK expert panel.Eye (London, England) · 2026Article
- Beyond Cost: Faricimab as a Driver of Service Efficiency and Quality in Neovascular Age-Related Macular Degeneration Care.Ophthalmology and therapy · 2026Article
- Serum Procalcitonin to Support Early Triage for Possible Systemic Infection in Patients with Endophthalmitis.Diagnostics (Basel, Switzerland) · 2026Article
- Mobile Laminar Airflow for Intravitreal Injections: Reducing Microbial Load at the Instrument Field.Journal of clinical medicine · 2026Article
- Intravitreal injection delivered volume under different environmental and training conditions.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Acute effects of intravitreal aflibercept injections on intraocular pressure in vitrectomized and silicone-oil-filled eyes: a prospective cohort study.Scientific reports · 2026Article
- Travel-associated emissions of intravitreal injections.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Comparison of Clinician Review Time and Confidence with Optical Coherence Tomography Digital versus Print-Based Workflows: A Pilot Observer Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Observational
- Therapeutic Evaluation of the Suprachoroidal Space for Stem Cell Delivery in Retinal Degeneration.Stem cells international · 2026Article
- The safety and effectiveness of anesthetic drops for intravitreal drug administration: a meta-analysis.Frontiers in medicine · 2026Review
- The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review.Health economics review · 2025Review
- Ten-Year Trends of Intravitreal Injection in South Korea Using the Health Insurance Review and Assessment Service Data.Korean journal of ophthalmology : KJO · 2025Observational
- Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective.PharmacoEconomics · 2025Article
- Towards greener intravitreal injections: the Oxford Eye Hospital experience.Eye (London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimsTo describe past trends and future projections for the number of intravitreal injections being administered at a large tertiary hospital in London, United Kingdom.
methodsRetrospective data from Moorfields Eye Hospital were collected using the electronic medical record system. Descriptive statistics were used to visualise overall trends. Time series forecasting was used to predict the number of injections that will be administered up to and including the year 2029.
resultsThe number of injections has increased nearly 11-fold from 2009 to 2019, with a total of 44,924 injections delivered in 2019. The majority of injections were given for the treatment of neovascular age-related macular degeneration. Aflibercept formed 87% of injections administered in 2019. The number of injections is predicted to continue to increase every year, with nearly 83,000 injections forecasted in the year 2029.
conclusionThe demand for intravitreal injections has increased substantially over the last decade and is predicted to further increase. Healthcare systems will need to adapt to accommodate the high demand. Other solutions may include longer-acting therapies to reduce the treatment burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.